Pimefylline

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C15H18N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8680B5Y37A, chemically known as 3,7-dihydro-1,3-dimethyl-7-(2-((3-pyridinylmethyl)amino)ethyl)-1h-purine-2,6-dione but generally known as pimefylline, which bears US NIH Compound Identifier 65597. European Medicines Agency schedules Pimefylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09837MIG. The term PIMEFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). PIMEFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pimefylline under HS 29395900 and SITC 54145. As of Q4 2014, PIMEFYLLINE remains the US FDA Preferred Term for this commodity. Pimefylline bears US NLM identifiers UMLS ID C1882379 and NCI Concept Code C66384. SMILES: O=c1n(c(=O)n(c2ncn(c12)CCNCc1cccnc1)C)C.